Company Filing History:
3 out of 4 
1 out of 1 
1 out of 1 Years Active: 1991-1998
Title: Avi Gertner: Innovator in Transdermal Drug Delivery
Introduction
Avi Gertner is a notable inventor based in Kfar Saba, Israel. He has made significant contributions to the field of pharmaceutical formulations, particularly in transdermal drug delivery systems. With a total of five patents to his name, Gertner's work focuses on enhancing the effectiveness of therapeutic proteins and polypeptides.
Latest Patents
Gertner's latest patents include innovative formulations that comprise therapeutically-active proteins or polypeptides. One of his notable inventions is a pharmaceutical formulation designed for transdermal administration. This formulation includes an aqueous emulsion or dispersion that contains an active ingredient, at least one therapeutically active protein or polypeptide, and a specific oil phase. The therapeutic activity of the active ingredient is detectable in the bloodstream within less than two hours after administration. Another significant patent involves a pharmaceutical composition for transdermal administration to both humans and animals. This composition includes a medicament adapted for transdermal delivery and a carrier selected from semisolids and liquids. The invention also encompasses a device for transdermal administration, which features a matrix for controlled release of the medicament.
Career Highlights
Throughout his career, Avi Gertner has worked with various companies, including Dermamed, Inc. and Pharmaderm Research & Development Ltd. His expertise in pharmaceutical formulations has positioned him as a key player in the development of advanced drug delivery systems.
Collaborations
Gertner has collaborated with professionals in the field, including his coworker, Yosef Rubinstein. Their joint efforts have contributed to the advancement of transdermal drug delivery technologies.
Conclusion
Avi Gertner's innovative work in transdermal drug delivery systems has the potential to significantly impact the pharmaceutical industry. His patents reflect a commitment to improving the efficacy of therapeutic treatments through advanced formulations.